Drug Profile
Tildrakizumab - Almirall/Sun Pharmaceutical Industries
Alternative Names: ILUMETRI; Ilumetri; ILUMYA; MK-3222; SCH-900222; SUNPG 1622; SUNPG 1622 I; SUNPG 1623 I; SUNPG 1623 II; SUNPG 1623 III; SUNPG 1623 IV; SUNPG1623; Tildrakizumab-asmnLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Almirall S.A.; China Medical System; Institute of Cancer Research; Merck & Co; Schering-Plough; Sun Pharmaceutical Industries
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-23 subunit p19 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Plaque psoriasis
- Preregistration Psoriatic arthritis
- Phase II/III Ankylosing spondylitis; Intervertebral disc degeneration; Non-radiographic axial spondyloarthritis
- Phase I/II Prostate cancer
- Discontinued Autoimmune disorders